Effect of combination therapy of methylfolate with antidepressants in patients with depressive disorder.

IF 2.7 3区 医学 Q2 PHARMACOLOGY & PHARMACY BMC Pharmacology & Toxicology Pub Date : 2025-01-22 DOI:10.1186/s40360-025-00846-x
Afifa Siddique, Muhammad Masood Khokhar, Akbar Waheed, Uzma Naeem, Shahzad Akhtar Aziz
{"title":"Effect of combination therapy of methylfolate with antidepressants in patients with depressive disorder.","authors":"Afifa Siddique, Muhammad Masood Khokhar, Akbar Waheed, Uzma Naeem, Shahzad Akhtar Aziz","doi":"10.1186/s40360-025-00846-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To determine the relative effectiveness of combination therapy of antidepressants with low-dose methylfolate versus antidepressant monotherapy in patients with depressive disorder.</p><p><strong>Methods: </strong>In an open-label clinical trial, forty-four patients with depressive disorder (6A70, 6A71, and 6A72 according to ICD-11) received an evidence-based antidepressant therapy (either escitalopram 10-20 mg, sertraline 50-100 mg, fluoxetine 20-40 mg, duloxetine 30-60 mg, mirtazapine 15-30 mg, venlafaxine 75-150 mg, trazodone 50-100 mg, amitriptyline 25-75 mg, or clomipramine 25-75 mg orally daily for 4 weeks). The experimental group, Group B was additionally given a dose of methylfolate 800 µg daily for four weeks. The psychometric testing of depression was achieved through administration of Patient Health Questionnaire-9 (PHQ-9) on days 0, 14, and 28, to find the improvement in the depressive score on day 28, the remission rate on day 28, and decrease in the time lag on day 14. Adverse effects were analyzed by self-assessment questionnaire to observe the tolerability. The paired sample t-test and the independent sample t-test were applied for analysis by using SPSS v27.0. The p-value ≤ 0.05 was considered statistically significant.</p><p><strong>Results: </strong>On day 28, patients on low dose methylfolate and antidepressant combination therapy showed a 40.33% improvement in depression symptoms, compared to 26.43% in patients on antidepressant monotherapy (p-value < 0.05). This treatment strategy had no effect on the time-lag of outcomes on day 14 and the remission rate on day 28 was not found statistically significant. Only one patient reported insomnia, while another mentioned irritability.</p><p><strong>Conclusion: </strong>Combination therapy of antidepressants with low-dose methylfolate may provide a safe and effective treatment strategy for patients with depressive disorder.</p><p><strong>Clinical trial identifier: </strong>NCT05931965.</p><p><strong>Clinicaltrials: </strong>gov. https://classic.</p><p><strong>Clinicaltrials: </strong>gov/ct2/show/NCT05931965.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"14"},"PeriodicalIF":2.7000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11752948/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40360-025-00846-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To determine the relative effectiveness of combination therapy of antidepressants with low-dose methylfolate versus antidepressant monotherapy in patients with depressive disorder.

Methods: In an open-label clinical trial, forty-four patients with depressive disorder (6A70, 6A71, and 6A72 according to ICD-11) received an evidence-based antidepressant therapy (either escitalopram 10-20 mg, sertraline 50-100 mg, fluoxetine 20-40 mg, duloxetine 30-60 mg, mirtazapine 15-30 mg, venlafaxine 75-150 mg, trazodone 50-100 mg, amitriptyline 25-75 mg, or clomipramine 25-75 mg orally daily for 4 weeks). The experimental group, Group B was additionally given a dose of methylfolate 800 µg daily for four weeks. The psychometric testing of depression was achieved through administration of Patient Health Questionnaire-9 (PHQ-9) on days 0, 14, and 28, to find the improvement in the depressive score on day 28, the remission rate on day 28, and decrease in the time lag on day 14. Adverse effects were analyzed by self-assessment questionnaire to observe the tolerability. The paired sample t-test and the independent sample t-test were applied for analysis by using SPSS v27.0. The p-value ≤ 0.05 was considered statistically significant.

Results: On day 28, patients on low dose methylfolate and antidepressant combination therapy showed a 40.33% improvement in depression symptoms, compared to 26.43% in patients on antidepressant monotherapy (p-value < 0.05). This treatment strategy had no effect on the time-lag of outcomes on day 14 and the remission rate on day 28 was not found statistically significant. Only one patient reported insomnia, while another mentioned irritability.

Conclusion: Combination therapy of antidepressants with low-dose methylfolate may provide a safe and effective treatment strategy for patients with depressive disorder.

Clinical trial identifier: NCT05931965.

Clinicaltrials: gov. https://classic.

Clinicaltrials: gov/ct2/show/NCT05931965.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
甲基叶酸与抗抑郁药联合治疗抑郁症的疗效观察。
目的:探讨抗抑郁药联合低剂量甲基叶酸与抗抑郁药单药治疗抑郁症患者的相对疗效。方法:在一项开放标签临床试验中,44例抑郁症患者(根据ICD-11, 6A70, 6A71和6A72)接受循证抗抑郁治疗(艾司西酞普兰10- 20mg,舍曲林50- 100mg,氟西汀20- 40mg,度洛西汀30- 60mg,米氮平15- 30mg,文拉法辛75- 150mg,曲唑酮50- 100mg,阿米替林25- 75mg,氯丙帕明25- 75mg,每日口服,持续4周)。实验组,B组在对照组基础上给予每日800µg甲基叶酸,连续4周。在第0、14、28天使用患者健康问卷-9 (PHQ-9)进行抑郁心理测量,观察第28天抑郁评分的改善、第28天缓解率的改善以及第14天时间滞后的减少。采用自评问卷对不良反应进行分析,观察耐受性。采用SPSS v27.0软件进行配对样本t检验和独立样本t检验。p值≤0.05认为有统计学意义。结果:第28天,低剂量甲基叶酸与抗抑郁药物联合治疗患者抑郁症状改善40.33%,而单药治疗患者抑郁症状改善26.43% (p值)结论:抗抑郁药物与低剂量甲基叶酸联合治疗可能是一种安全有效的治疗抑郁症患者的策略。临床试验标识:NCT05931965。临床试验:gov. https://classic.Clinicaltrials: gov/ct2/show/NCT05931965。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BMC Pharmacology & Toxicology
BMC Pharmacology & Toxicology PHARMACOLOGY & PHARMACYTOXICOLOGY&nb-TOXICOLOGY
CiteScore
4.80
自引率
0.00%
发文量
87
审稿时长
12 weeks
期刊介绍: BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials and toxicology.
期刊最新文献
Comparative study of cardio-protective effect of metformin versus dapagliflozin in experimentally induced myocardial infarction in diabetic rats. Experimental evaluation of N-acetylcysteine against doxorubicin cardiotoxicity in rats. Effect of hydroxychloroquine pre-treatment on acute radiosensitivity of thyroid in young rats. Melatonin mitigates methamphetamine-induced testicular oxidative stress, hormonal imbalance and seminiferous tubule degeneration in rats. In vitro comparative quality evaluation of different brands of metformin hydrochloride tablets available in Mekelle City, Tigray Regional State, Ethiopia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1